FI67371C - Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner - Google Patents
Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner Download PDFInfo
- Publication number
- FI67371C FI67371C FI814080A FI814080A FI67371C FI 67371 C FI67371 C FI 67371C FI 814080 A FI814080 A FI 814080A FI 814080 A FI814080 A FI 814080A FI 67371 C FI67371 C FI 67371C
- Authority
- FI
- Finland
- Prior art keywords
- compound
- group
- formula
- carbon atoms
- hcl
- Prior art date
Links
- 230000000144 pharmacologic effect Effects 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 68
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 52
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 24
- 239000002253 acid Substances 0.000 claims abstract description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 21
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 18
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 188
- 238000000034 method Methods 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 57
- -1 carboxylic acid halide Chemical class 0.000 claims description 29
- 230000009467 reduction Effects 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 239000012948 isocyanate Substances 0.000 claims description 13
- 150000002513 isocyanates Chemical class 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 238000005804 alkylation reaction Methods 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 230000029936 alkylation Effects 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 150000003949 imides Chemical class 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000005336 allyloxy group Chemical group 0.000 claims description 3
- 150000002430 hydrocarbons Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 37
- 239000007858 starting material Substances 0.000 abstract description 13
- 239000000543 intermediate Substances 0.000 abstract description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 147
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 104
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 104
- 229960003638 dopamine Drugs 0.000 description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 35
- 239000002585 base Substances 0.000 description 33
- 230000001242 postsynaptic effect Effects 0.000 description 33
- 102000007527 Autoreceptors Human genes 0.000 description 32
- 108010071131 Autoreceptors Proteins 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 32
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000001704 evaporation Methods 0.000 description 20
- 230000008020 evaporation Effects 0.000 description 20
- 239000003054 catalyst Substances 0.000 description 18
- 229910010082 LiAlH Inorganic materials 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 16
- 229960004046 apomorphine Drugs 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 15
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 14
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 14
- 229960003147 reserpine Drugs 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 210000005036 nerve Anatomy 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 230000008485 antagonism Effects 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 229960003878 haloperidol Drugs 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 210000001577 neostriatum Anatomy 0.000 description 10
- 229940044601 receptor agonist Drugs 0.000 description 10
- 239000000018 receptor agonist Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000084978 Rena Species 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 230000037023 motor activity Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000001994 activation Methods 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000002197 limbic effect Effects 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 description 6
- QWAMJXOIACKDRQ-UHFFFAOYSA-N 3-(phenoxymethyl)pyridine Chemical compound C=1C=CN=CC=1COC1=CC=CC=C1 QWAMJXOIACKDRQ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000001033 ether group Chemical group 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003176 neuroleptic agent Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000003518 presynaptic effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 5
- PNBOVBWIGKATIC-UHFFFAOYSA-N 3-(1-propylpiperidin-3-yl)phenol;hydrobromide Chemical compound Br.C1N(CCC)CCCC1C1=CC=CC(O)=C1 PNBOVBWIGKATIC-UHFFFAOYSA-N 0.000 description 5
- NRHUDETYKUBQJT-UHFFFAOYSA-N 3-(1-propylpiperidin-3-yl)phenol;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(O)=C1 NRHUDETYKUBQJT-UHFFFAOYSA-N 0.000 description 5
- RJKICHMOAGTIDI-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1C1=CC=CC(OC)=C1 RJKICHMOAGTIDI-UHFFFAOYSA-N 0.000 description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 4
- ULPCAXBPJAGPSP-UHFFFAOYSA-N 3-(1-propanoylpiperidin-3-yl)benzoic acid Chemical compound C1N(C(=O)CC)CCCC1C1=CC=CC(C(O)=O)=C1 ULPCAXBPJAGPSP-UHFFFAOYSA-N 0.000 description 4
- GWLUVEXOMYTFLE-UHFFFAOYSA-N 3-(1-propylpiperidin-3-yl)aniline;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(N)=C1 GWLUVEXOMYTFLE-UHFFFAOYSA-N 0.000 description 4
- SDYPHBZWZMXURT-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OC)=C1 SDYPHBZWZMXURT-UHFFFAOYSA-N 0.000 description 4
- FWJGHQRTPNUZIV-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1-propylpyrrolidine Chemical compound C1N(CCC)CCC1C1=CC=CC(OC)=C1 FWJGHQRTPNUZIV-UHFFFAOYSA-N 0.000 description 4
- LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 description 4
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 4
- HYUOAVGLJXTEGX-UHFFFAOYSA-N 3-piperidin-3-ylphenol Chemical compound OC1=CC=CC(C2CNCCC2)=C1 HYUOAVGLJXTEGX-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229920000945 Amylopectin Polymers 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000001263 acyl chlorides Chemical class 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000003715 limbic system Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- MGRCIJOTXSRFHT-UHFFFAOYSA-N methyl 3-(1-propanoylpiperidin-3-yl)benzoate Chemical compound C1N(C(=O)CC)CCCC1C1=CC=CC(C(=O)OC)=C1 MGRCIJOTXSRFHT-UHFFFAOYSA-N 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000000701 neuroleptic effect Effects 0.000 description 4
- 239000012434 nucleophilic reagent Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 4
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 4
- JSUCBDBLOLGQGF-UHFFFAOYSA-M 3-(3-methoxyphenyl)-1-propylpyridin-1-ium;bromide Chemical group [Br-].CCC[N+]1=CC=CC(C=2C=C(OC)C=CC=2)=C1 JSUCBDBLOLGQGF-UHFFFAOYSA-M 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000011260 aqueous acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000001653 corpus striatum Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- HLFKAFNNGCVRIQ-UHFFFAOYSA-N methyl 3-pyridin-3-ylbenzoate Chemical compound COC(=O)C1=CC=CC(C=2C=NC=CC=2)=C1 HLFKAFNNGCVRIQ-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- GEWWCWZGHNIUBW-UHFFFAOYSA-N 1-(4-nitrophenyl)propan-2-one Chemical compound CC(=O)CC1=CC=C([N+]([O-])=O)C=C1 GEWWCWZGHNIUBW-UHFFFAOYSA-N 0.000 description 2
- BMHUPZKRSCBLKZ-UHFFFAOYSA-N 1-[3-(3-methoxyphenyl)piperidin-1-yl]butan-1-one Chemical compound C1N(C(=O)CCC)CCCC1C1=CC=CC(OC)=C1 BMHUPZKRSCBLKZ-UHFFFAOYSA-N 0.000 description 2
- RMHHULCXUGPLGV-UHFFFAOYSA-N 1-[3-(3-methoxyphenyl)pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1C1=CC=CC(OC)=C1 RMHHULCXUGPLGV-UHFFFAOYSA-N 0.000 description 2
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 2
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- HTSCVTLWZAQUOE-UHFFFAOYSA-N 1-butyl-3-(3-methoxyphenyl)piperidine;hydrochloride Chemical compound Cl.C1N(CCCC)CCCC1C1=CC=CC(OC)=C1 HTSCVTLWZAQUOE-UHFFFAOYSA-N 0.000 description 2
- BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 2
- CFLAYISSADVCJH-UHFFFAOYSA-N 2,6-dimethylbenzoyl chloride Chemical compound CC1=CC=CC(C)=C1C(Cl)=O CFLAYISSADVCJH-UHFFFAOYSA-N 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- ITXBDHMIXPKNIE-UHFFFAOYSA-N 3-(1-butylpiperidin-3-yl)phenol Chemical compound C1N(CCCC)CCCC1C1=CC=CC(O)=C1 ITXBDHMIXPKNIE-UHFFFAOYSA-N 0.000 description 2
- BABGLWPMISPDRK-UHFFFAOYSA-N 3-(1-pentylpiperidin-3-yl)phenol;hydrochloride Chemical compound Cl.C1N(CCCCC)CCCC1C1=CC=CC(O)=C1 BABGLWPMISPDRK-UHFFFAOYSA-N 0.000 description 2
- VRNBZJJBPKLDAO-UHFFFAOYSA-N 3-(1-propan-2-ylpiperidin-3-yl)phenol Chemical compound C1N(C(C)C)CCCC1C1=CC=CC(O)=C1 VRNBZJJBPKLDAO-UHFFFAOYSA-N 0.000 description 2
- UKVZMGSVCWZTLW-UHFFFAOYSA-N 3-(1-propylpyridin-1-ium-3-yl)phenol bromide Chemical group [Br-].OC=1C=C(C=CC=1)C=1C=[N+](C=CC=1)CCC UKVZMGSVCWZTLW-UHFFFAOYSA-N 0.000 description 2
- WPYVGSUSOOZONM-UHFFFAOYSA-N 3-(1-propylpyrrolidin-3-yl)phenol Chemical compound C1N(CCC)CCC1C1=CC=CC(O)=C1 WPYVGSUSOOZONM-UHFFFAOYSA-N 0.000 description 2
- GEPMFAMTOUUGTK-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1-propylpiperidine;hydrobromide Chemical compound Br.C1N(CCC)CCCC1C1=CC=CC(OC)=C1 GEPMFAMTOUUGTK-UHFFFAOYSA-N 0.000 description 2
- KTJLKTQSWVXPPM-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine;hydrochloride Chemical compound Cl.COC1=CC=CC(C2CNCCC2)=C1 KTJLKTQSWVXPPM-UHFFFAOYSA-N 0.000 description 2
- HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 description 2
- MDZWFRVPKYMLPL-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2CNCC2)=C1 MDZWFRVPKYMLPL-UHFFFAOYSA-N 0.000 description 2
- LONDBHTYIYKOCM-UHFFFAOYSA-N 3-(3-methylphenyl)pyridine Chemical compound CC1=CC=CC(C=2C=NC=CC=2)=C1 LONDBHTYIYKOCM-UHFFFAOYSA-N 0.000 description 2
- ARUNMVWEUWHFPG-UHFFFAOYSA-N 3-(3-phenylmethoxyphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OCC=2C=CC=CC=2)=C1 ARUNMVWEUWHFPG-UHFFFAOYSA-N 0.000 description 2
- QOXJWHAYYZUAHR-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol;hydrochloride Chemical compound Cl.NNCC1=CC=CC(O)=C1 QOXJWHAYYZUAHR-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 2
- JBPMHBLMULBWFU-UHFFFAOYSA-N 4-(1-propylpiperidin-3-yl)benzene-1,2-diol Chemical group C1N(CCC)CCCC1C1=CC=C(O)C(O)=C1 JBPMHBLMULBWFU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- YDIYIDYMYMDVIL-UHFFFAOYSA-N CC=1C=C(C=CC1)C=1C=NC=CC1.CC=1C=C(C=CC1)C=1C=NC=CC1 Chemical compound CC=1C=C(C=CC1)C=1C=NC=CC1.CC=1C=C(C=CC1)C=1C=NC=CC1 YDIYIDYMYMDVIL-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 230000006181 N-acylation Effects 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- FCSLJQQSIPTVNB-UHFFFAOYSA-N [3-(1-propylpiperidin-3-yl)phenyl] acetate;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OC(C)=O)=C1 FCSLJQQSIPTVNB-UHFFFAOYSA-N 0.000 description 2
- LNTXEBVGNPZJJV-UHFFFAOYSA-N [3-(1-propylpiperidin-3-yl)phenyl] benzoate;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OC(=O)C=2C=CC=CC=2)=C1 LNTXEBVGNPZJJV-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VNEBWJSWMVTSHK-UHFFFAOYSA-L disodium;3-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=CC2=C1 VNEBWJSWMVTSHK-UHFFFAOYSA-L 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000009097 homeostatic mechanism Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FKUUDDGRDRPAQQ-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=C[C-]=C1 FKUUDDGRDRPAQQ-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 125000006682 monohaloalkyl group Chemical group 0.000 description 2
- 230000001095 motoneuron effect Effects 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- ZBRJXVVKPBZPAN-UHFFFAOYSA-L nickel(2+);triphenylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Ni+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 ZBRJXVVKPBZPAN-UHFFFAOYSA-L 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009090 positive inotropic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001718 repressive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000012485 toluene extract Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007723 transport mechanism Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 1
- GZGYOLIWTUXMAR-UHFFFAOYSA-N 1-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(N2CCCCC2)=C1 GZGYOLIWTUXMAR-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-N 2,2-diethylpropanedioic acid Chemical class CCC(CC)(C(O)=O)C(O)=O LTMRRSWNXVJMBA-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- QTYFKXPXLCCNOF-UHFFFAOYSA-N 3-(1-pentylpiperidin-3-yl)phenol Chemical compound C1N(CCCCC)CCCC1C1=CC=CC(O)=C1 QTYFKXPXLCCNOF-UHFFFAOYSA-N 0.000 description 1
- JQISQMHONBYOCE-UHFFFAOYSA-N 3-(1-propylpiperidin-3-yl)aniline Chemical compound C1N(CCC)CCCC1C1=CC=CC(N)=C1 JQISQMHONBYOCE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical class OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PGQKOKKKLJXHKF-UHFFFAOYSA-N CCCCCC1(CCCNC1)C2=CC(=CC=C2)O Chemical compound CCCCCC1(CCCNC1)C2=CC(=CC=C2)O PGQKOKKKLJXHKF-UHFFFAOYSA-N 0.000 description 1
- 101100334117 Caenorhabditis elegans fah-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- KXEMQEGRZWUKJS-UHFFFAOYSA-N Raufloridine Natural products COC1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 KXEMQEGRZWUKJS-UHFFFAOYSA-N 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- MVHBZQNGIJYPBL-UHFFFAOYSA-N [3-(1-propylpiperidin-3-yl)phenyl] 2,6-dimethylbenzoate;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OC(=O)C=2C(=CC=CC=2C)C)=C1 MVHBZQNGIJYPBL-UHFFFAOYSA-N 0.000 description 1
- IOMFBAIOVCLWEQ-UHFFFAOYSA-N [3-(1-propylpiperidin-3-yl)phenyl] n-phenylcarbamate;hydrochloride Chemical compound Cl.C1N(CCC)CCCC1C1=CC=CC(OC(=O)NC=2C=CC=CC=2)=C1 IOMFBAIOVCLWEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003374 anti-dyskinetic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001731 carboxylic acid azides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- ZTHNOZQGTXKVNZ-UHFFFAOYSA-L dichloroaluminum Chemical compound Cl[Al]Cl ZTHNOZQGTXKVNZ-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- INIZTEMZWOJCAF-UHFFFAOYSA-J dimagnesium octadecanoate Chemical class [Mg+2].[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O INIZTEMZWOJCAF-UHFFFAOYSA-J 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000010881 fly ash Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001962 neuropharmacologic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 230000028838 turning behavior Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Polyamides (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI831681A FI831681A0 (fi) | 1979-12-05 | 1980-12-05 | Nya foereningar som aer anvaendbara som mellanprodukter vid framstaellning av farmakologiskt aktivafenyl-azacyklo-alkaner |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7910026 | 1979-12-05 | ||
SE7910026 | 1979-12-05 | ||
PCT/SE1980/000319 WO1981001552A1 (en) | 1979-12-05 | 1980-12-05 | New phenyl-azacycloalkanes |
SE8000319 | 1980-12-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI814080L FI814080L (fi) | 1981-12-18 |
FI67371B FI67371B (fi) | 1984-11-30 |
FI67371C true FI67371C (fi) | 1985-03-11 |
Family
ID=20339477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI814080A FI67371C (fi) | 1979-12-05 | 1981-12-18 | Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner |
Country Status (17)
Country | Link |
---|---|
US (1) | US4426386A (en16) |
EP (2) | EP0084920B1 (en16) |
JP (1) | JPS6135175B2 (en16) |
AT (1) | ATE42281T1 (en16) |
AU (1) | AU542153B2 (en16) |
CA (1) | CA1147339A (en16) |
DD (1) | DD155065A5 (en16) |
DE (1) | DE3070247D1 (en16) |
DK (1) | DK155793C (en16) |
ES (3) | ES497489A0 (en16) |
FI (1) | FI67371C (en16) |
GR (1) | GR72841B (en16) |
HU (1) | HU185422B (en16) |
IE (1) | IE50674B1 (en16) |
PT (1) | PT72172B (en16) |
SE (1) | SE8107742L (en16) |
WO (1) | WO1981001552A1 (en16) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8305362D0 (sv) * | 1983-09-30 | 1983-09-30 | Astra Laekemedel Ab | Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds |
US4937346A (en) * | 1979-12-05 | 1990-06-26 | Per Arvid Emil Carlsson | Phenyl-azacykloalkanes |
SE446335B (sv) * | 1982-03-30 | 1986-09-01 | Astra Laekemedel Ab | Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin |
EP0077607A1 (en) * | 1981-09-17 | 1983-04-27 | Beecham Group Plc | N-substituted 3-aryl piperidines and derivatives thereof |
US4719219A (en) * | 1982-03-30 | 1988-01-12 | Per A. E. Carlsson | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders |
EP0105243B1 (de) * | 1982-10-01 | 1988-08-03 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Spaltung von rac. 1-Propyl-3-aryl-piperidinen |
US4593037A (en) * | 1984-07-26 | 1986-06-03 | Pfizer Inc. | 1,3-disubstituted piperidine compounds as neuroleptic agents |
JPH0657695B2 (ja) * | 1985-07-12 | 1994-08-03 | エーザイ株式会社 | 4−シアノピペリジン誘導体 |
US4826869A (en) * | 1988-02-19 | 1989-05-02 | Syntex (U.S.A.) Inc. | N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines |
DE3930282A1 (de) * | 1989-09-11 | 1991-03-21 | Boehringer Ingelheim Kg | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit |
GB9113031D0 (en) * | 1991-06-17 | 1991-08-07 | Smithkline Beecham Plc | Compounds |
SE9802546D0 (sv) * | 1998-07-15 | 1998-07-15 | Ross Nicholas Waters | Medicinal product and method for treatment and prevention of dyskinesia |
NZ514560A (en) * | 1999-03-31 | 2004-02-27 | Univ Arizona Foundation | Viral treatment |
US7346938B2 (en) * | 2002-08-02 | 2008-03-25 | Roy W. Mattson, Jr. | Retrofit suction sanitation safety cover |
EP1707558A1 (en) * | 2005-03-21 | 2006-10-04 | Ferrer Internacional, S.A. | Benzoic acid ester compounds, compositions, uses and methods related thereto |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2892842A (en) | 1959-06-30 | Their preparation | ||
DE1144279B (de) * | 1957-09-26 | 1963-02-28 | Robins Co Inc A H | Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen |
FR1248129A (fr) * | 1959-02-12 | 1960-12-09 | Mead Johnson & Co | Procédé de préparation des 1-acyl- et 1-carbalkoxy-3 pyrrolidinols |
US2975193A (en) * | 1959-06-18 | 1961-03-14 | Parke Davis & Co | Organic amine compounds and method of obtaining the same |
NO116115B (en16) * | 1962-06-01 | 1969-02-03 | Parke Davis & Co | |
DK104980C (da) * | 1962-06-20 | 1966-08-01 | Parke Davis & Company A Corp O | Fremgangsmåde til fremstilling af optisk aktive eller racemiske 1-methylpyrrolidinderivater eller syreadditionssalte deraf. |
DK105337C (da) * | 1962-06-20 | 1966-09-19 | Parke Davis & Company A Corp O | Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidinforbindelser eller syreadditionssalte deraf. |
DK104736C (da) * | 1962-06-20 | 1966-06-27 | Parke Davis & Company A Corp O | Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidin-derivater eller syreadditionssalte deraf. |
DE1470155A1 (de) * | 1963-04-11 | 1969-06-04 | Parke Davis & Co | Neue Pyrrolidinverbindungen,ihre Saeureadditionssalze,sowie Verfahren zu deren Herstellung |
GB1012008A (en) * | 1963-08-01 | 1965-12-01 | Parke Davis & Co | Process for the production of pyrrolidine compounds |
GB1198973A (en) | 1969-02-07 | 1970-07-15 | Parke Davis & Co | Pyrrolidine Compounds with an Unsaturated Substituent and Methods for their Production |
US3647790A (en) * | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
CH526536A (de) * | 1970-02-05 | 1972-08-15 | Sandoz Ag | Verfahren zur Herstellung neuer 3-Phenylpyrrolidinderivate |
GB1283452A (en) * | 1970-07-24 | 1972-07-26 | Parke Davis & Co | Substituted 1,3-dialkylpyrrolidines and processes for their production |
US3970656A (en) * | 1974-06-11 | 1976-07-20 | Government Of The United States | 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines |
FR2310761A1 (fr) | 1975-05-16 | 1976-12-10 | Roussel Uclaf | Nouveaux derives de la phenyl-piperidine et leurs sels, procede de preparation et application a titre de medicaments |
FR2310762A1 (fr) | 1975-05-16 | 1976-12-10 | Roussel Uclaf | Nouveaux derives n-substitues de la phenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments |
DE2701705A1 (de) * | 1976-01-28 | 1977-08-04 | Sandoz Ag | Neue organische verbindungen, ihre verwendung und herstellung |
FR2340734A1 (fr) * | 1976-02-13 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de la m-trifluoromethylphenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments |
FR2380261A2 (fr) * | 1977-02-11 | 1978-09-08 | Roussel Uclaf | Nouveaux derives de la m-trifluoromethylphenylpiperidine et leurs sels, procede de preparation et application a titre de medicaments |
-
1980
- 1980-12-05 AU AU66426/81A patent/AU542153B2/en not_active Ceased
- 1980-12-05 US US06/213,633 patent/US4426386A/en not_active Expired - Lifetime
- 1980-12-05 ES ES497489A patent/ES497489A0/es active Granted
- 1980-12-05 DD DD80225781A patent/DD155065A5/de not_active IP Right Cessation
- 1980-12-05 CA CA000366280A patent/CA1147339A/en not_active Expired
- 1980-12-05 EP EP83200131A patent/EP0084920B1/en not_active Expired
- 1980-12-05 GR GR63561A patent/GR72841B/el unknown
- 1980-12-05 IE IE2545/80A patent/IE50674B1/en not_active IP Right Cessation
- 1980-12-05 AT AT83200131T patent/ATE42281T1/de active
- 1980-12-05 PT PT72172A patent/PT72172B/pt not_active IP Right Cessation
- 1980-12-05 HU HU811212A patent/HU185422B/hu not_active IP Right Cessation
- 1980-12-05 WO PCT/SE1980/000319 patent/WO1981001552A1/en active IP Right Grant
- 1980-12-05 JP JP56500175A patent/JPS6135175B2/ja not_active Expired
- 1980-12-05 DE DE8080850183T patent/DE3070247D1/de not_active Expired
- 1980-12-05 EP EP80850183A patent/EP0030526B1/en not_active Expired
-
1981
- 1981-07-31 DK DK342881A patent/DK155793C/da not_active IP Right Cessation
- 1981-12-16 ES ES508029A patent/ES8300703A1/es not_active Expired
- 1981-12-16 ES ES508030A patent/ES8300092A1/es not_active Expired
- 1981-12-18 FI FI814080A patent/FI67371C/fi not_active IP Right Cessation
- 1981-12-23 SE SE8107742A patent/SE8107742L/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PT72172A (en) | 1981-01-01 |
FI814080L (fi) | 1981-12-18 |
ES508030A0 (es) | 1982-10-01 |
JPS6135175B2 (en16) | 1986-08-12 |
WO1981001552A1 (en) | 1981-06-11 |
US4426386A (en) | 1984-01-17 |
ES8300092A1 (es) | 1982-10-01 |
EP0084920A2 (en) | 1983-08-03 |
AU6642681A (en) | 1981-06-19 |
ES508029A0 (es) | 1982-11-01 |
PT72172B (en) | 1982-07-05 |
HU185422B (en) | 1985-02-28 |
FI67371B (fi) | 1984-11-30 |
IE50674B1 (en) | 1986-06-11 |
EP0030526A1 (en) | 1981-06-17 |
DK342881A (da) | 1981-07-31 |
DK155793C (da) | 1989-10-02 |
ES8300703A1 (es) | 1982-11-01 |
ES8205768A1 (es) | 1982-08-01 |
DE3070247D1 (en) | 1985-04-04 |
JPS56501679A (en16) | 1981-11-19 |
EP0084920A3 (en) | 1985-05-22 |
DD155065A5 (de) | 1982-05-12 |
SE8107742L (sv) | 1981-12-23 |
IE802545L (en) | 1981-06-05 |
EP0084920B1 (en) | 1989-04-19 |
CA1147339A (en) | 1983-05-31 |
AU542153B2 (en) | 1985-02-07 |
ATE42281T1 (de) | 1989-05-15 |
ES497489A0 (es) | 1982-08-01 |
GR72841B (en16) | 1983-12-07 |
EP0030526B1 (en) | 1985-02-27 |
DK155793B (da) | 1989-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI67371C (fi) | Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner | |
Hacksell et al. | 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity | |
FI78067B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat och en vid foerfarandet anvaend mellanprodukt. | |
US20010051633A1 (en) | Subtype-selective NMDA receptor ligands and the use thereof | |
US20110160223A1 (en) | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | |
JP7463318B2 (ja) | 6員アザヘテロ環を含有するデルタ-オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法 | |
NO174044B (no) | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt amid-derivat | |
KR20220137085A (ko) | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 | |
HUE028329T2 (en) | 2-Phenylethylamino derivatives acting as calcium and / or sodium channel modulators | |
CA2217197A1 (en) | Novel heterocyclic compounds | |
EP2521714B1 (en) | Aromatic sulfone compounds useful in the treatment of central nervous disorders | |
US20130324550A1 (en) | 1-(2-phenoxymethylheteroaryl) piperidine and piperazine compounds | |
CN105008345A (zh) | 可用作gpr120的激动剂的双环吡咯衍生物 | |
EP3582783B1 (en) | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
CN116478134B (zh) | Ssri/5-ht1a双靶点抗抑郁甲酰哌啶类化合物及其制备方法和应用 | |
US4719219A (en) | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders | |
NO142395B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydro-1h-azepiner | |
CS215038B2 (en) | Method of making the hexahydro-1,4-oxazepins | |
CN103420898B (zh) | 二芳基哌啶类衍生物及其作为多靶点抗抑郁症药物的应用 | |
DK162214B (da) | Analogifremgangsmaade til fremstilling af en ren enantiomer af 3-fenyl-n-n-propylpiperidinderivater | |
US4937346A (en) | Phenyl-azacykloalkanes | |
Herrera Arozamena | Melatonin-and resveratrol-based multitarget-directed agents for Alzheimer's disease and photoswitchable muscular nicotinic receptor ligands | |
HK40083469A (en) | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
JPS6022711B2 (ja) | トランス−デカハイドロキノリン誘導体,その製造法,及びそれを含む医薬 | |
CA2566937A1 (en) | Substituted 2,5-diaminomethyl-1h-pyrroles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed |
Owner name: CARLSSON, PER ARVID EMIL |